Brind.
  1. Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.

Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.

1 report, 1 independent Updated Jun 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.

Who's involved

What this event is mainly about
Jazz Pharmaceuticals

Keep exploring

Part of

Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped